A prospective trial evaluating the safety and efficacy of Dianhydrogalactitol (VAL-083) in pediatric patients with medulloblastoma (MB) and high grade gliomas (HGG)

Trial Profile

A prospective trial evaluating the safety and efficacy of Dianhydrogalactitol (VAL-083) in pediatric patients with medulloblastoma (MB) and high grade gliomas (HGG)

Planning
Phase of Trial: Phase I

Latest Information Update: 07 Sep 2016

At a glance

  • Drugs Dianhydrogalactitol (Primary)
  • Indications Glioma; Medulloblastoma
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Sep 2016 According to Del Mar Pharmaceuticals media release,VAL-083 has received orphan drug designation in the U.S.
    • 19 Nov 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top